FDA Alerts on Epinephrine Injection Shortage: Distribution Implications for Wholesale Drug Distributors

The FDA issued a Drug Shortage Database alert on January 16, 2025, reporting the discontinuation of epinephrine injection, USP 30 mg/30 mL (1 mg/mL) multiple-dose vials by Amphastar Pharmaceuticals. This discontinuation affects wholesale drug distributors' emergency medication inventory management and introduces allocation protocol requirements under the FDA's critical drug shortage framework established in Section 506C of the Federal Food, Drug, and Cosmetic Act.

Regulatory Context

The FDA Drug Shortage Database tracks discontinuations and supply disruptions of medically necessary drugs under authority granted by the FDA Safety and Innovation Act (FDASIA) of 2012. Section 506C requires manufacturers to notify the FDA at least six months before discontinuing a drug that is life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition. Epinephrine injections qualify as life-supporting under this definition due to their use in anaphylaxis treatment.

Wholesale drug distributors operating under state licensure and 21 CFR Part 205 must manage controlled allocation when the FDA identifies a drug as in shortage. While the FDA does not mandate specific allocation methods, distributors face compliance scrutiny from state boards of pharmacy if allocation practices are deemed inequitable or if priority customers (hospitals, emergency medical services) experience supply gaps.

Discontinuation Details

Amphastar Pharmaceuticals discontinued the 30 mg/30 mL epinephrine injection vial effective Q4 2024. The FDA database lists the product status as "discontinued" with no projected restart date. The affected NDC is 55390-001-30. This formulation represented a significant portion of multi-dose epinephrine supply used in institutional settings, including hospitals and ambulatory surgery centers.

Alternative epinephrine formulations remain available, including:

• Epinephrine auto-injectors (EpiPen, generic equivalents) — single-dose, pre-filled
• Epinephrine ampules and single-dose vials (1 mg/1 mL)
• Compounded epinephrine preparations (limited to 503B outsourcing facilities under FDA oversight)

The discontinuation does not affect epinephrine API (active pharmaceutical ingredient) availability. Manufacturing capacity constraints and commercial decisions drove the discontinuation, not raw material shortages.

Wholesaler Operational Implications

Wholesale drug distributors must now address three immediate operational challenges:

Inventory reallocation. Existing stock of the discontinued vial must be allocated to existing customers rather than new orders. Distributors holding inventory as of January 2025 face competing demands from hospitals seeking to stockpile before supply exhausts. State boards of pharmacy in California, New York, and Texas have historically investigated distributors that allocated remaining stock to highest-bidding customers rather than established accounts during prior epinephrine shortages (2018 EpiPen shortage precedent).

Substitution guidance. Distributors must communicate alternative product availability to pharmacy and hospital procurement teams. The shift from multi-dose vials to single-dose ampules increases per-dose costs and requires different storage and handling protocols. Wholesale drug distributors are not permitted to recommend therapeutic substitutions (this is a prescriber function), but operational guidance on product availability falls within standard distribution services.

Emergency medication distribution priority. Epinephrine qualifies as an emergency medication under most state pharmacy laws. Distributors maintaining emergency pharmaceutical supply contracts with hospitals, EMS systems, and disaster response agencies must ensure continuity. Failure to prioritize these accounts during a shortage can trigger breach-of-contract claims and state board of pharmacy investigations. The 2020 COVID-19 emergency medication distribution orders (state-level emergency declarations) set precedent for priority allocation frameworks, though no current federal allocation mandate exists for epinephrine.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in the ColdChainCheck directory, 1,234 hold active FDA registration—the baseline requirement for distributing prescription drugs in interstate commerce. However, the average compliance score of 51/100 indicates that fewer than half of tracked entities maintain full verification across all six compliance dimensions (state licensure, NABP accreditation, FDA registration, recall history, enforcement actions, and corporate registration).

During drug shortage events, distributors with higher compliance scores typically demonstrate more robust inventory management and allocation documentation capabilities. The 28 entities in the "Excellent" tier (76-100 points) represent 2.2% of the tracked population—these are the distributors most likely to maintain documented allocation protocols that satisfy state board of pharmacy scrutiny during shortage investigations.

The 73 entities with FDA recalls on record warrant particular attention during shortage periods. Historical recall data correlates with higher risk of allocation irregularities, as entities with prior compliance failures are statistically more likely to deprioritize documentation during high-demand periods. QA managers evaluating epinephrine supply chain partners should cross-reference recall history against current shortage exposure.

Practical Steps for Compliance and Procurement Teams

Verify distributor FDA registration status. Use the ColdChainCheck directory to confirm that your epinephrine suppliers hold current FDA registration. Filter by state and review the compliance score breakdown to identify which data points are verified. Entities with expired or suspended FDA registration cannot legally distribute the drug in interstate commerce, regardless of inventory availability.

Check NABP accreditation for emergency medication suppliers. Only 63 entities in the directory hold NABP accreditation (formerly VAWD). Accredited distributors undergo third-party verification of their quality systems, inventory controls, and pedigree documentation—critical factors during allocation decisions. If your primary epinephrine distributor is not NABP-accredited, request documentation of their allocation methodology in writing. For background on accreditation requirements, see the NABP VAWD accreditation guide.

Document allocation communications. If your distributor restricts epinephrine orders or allocates partial shipments, request written confirmation of the allocation criteria. State boards of pharmacy in California (16 CCR 1780), New York (10 NYCRR 63.6), and Florida (Rule 64B16-27.300) require distributors to maintain records justifying allocation decisions during shortages. Your procurement documentation may be reviewed during facility inspections.

Monitor alternative product availability through multiple distributors. The shift from multi-dose vials to single-dose ampules may require sourcing from distributors who do not carry your primary product line. Use ColdChainCheck's state license filters to identify backup distributors licensed in your jurisdiction. Entities with compliance scores below 40/100 should be deprioritized unless no alternatives exist—low scores typically reflect incomplete licensure coverage or data gaps that increase supply chain risk.

ColdChainCheck tracks FDA drug shortage alerts and updates entity compliance scores as new enforcement actions or recalls are published. For ongoing coverage of DSCSA compliance and wholesale distributor regulatory developments, see the regulatory guides section.

Disclaimer: This article provides informational analysis of FDA drug shortage alerts and wholesale distributor compliance obligations. It is not legal or regulatory advice. Verify all compliance requirements with your legal counsel and the relevant state board of pharmacy.